Skip to main content

Advertisement

Fig. 2 | Molecular Neurodegeneration

Fig. 2

From: The N17 domain mitigates nuclear toxicity in a novel zebrafish Huntington’s disease model

Fig. 2

mHTT-∆N17-exon1 transgenic fish develop a progressive motor behavior phenotype. a Panels taken from Additional file 1: Movie S1 showing normal swimming behavior in a HTT-ΔN17-exon1 transgenic fish. b Panels taken from Additional file 3: Movie S3 showing abnormal swimming behavior, corkscrew swimming, in a mHTT-ΔN17-exon1 transgenic fish. c Disease free survival curve for each HTT-exon1 transgenic line corresponding to disease onset. Note that mHTT-ΔN17-exon1 L1 (n = 10) and L2 (n = 24) both develop symptoms earlier than mHTT-exon1 L1 (n = 16) and that mHTT-exon1 L2 (n = 16), HTT-exon1 (n = 21), and HTT-ΔN17-exon1 (n = 26) do not exhibit symptoms in the observed time frame. Kaplan Meier analysis with Log Rank test, p < 0.001 for mHTT-ΔN17-exon1 L1, mHTT-ΔN17-exon1 L2, and mHTT-exon1 L1. d Behavioral characterization within different transgenic lines. Behavior was grouped into four categories: Healthy, Stage 1, Stage 2, or Stage 3 as described. Observations were made weekly. e Disease progression of mHTT-exon1 L1 fish. Note the discontinuous x-axis to account for the extended time frame of behavioral changes (n = 18). f Disease progression of mHTT-ΔN17-exon1 L1. mHTT-ΔN17-exon1 L1 fish developed a robust, progressive motor behavioral deterioration beginning at 5–8 weeks of age and progressing to immobility and death by 12 weeks (n = 10)

Back to article page